Epidemiology

Rivus Pharmaceuticals Announces Expansion of HU6 Clinical Program and New Leadership Appointments

Retrieved on: 
Wednesday, November 15, 2023
Accounting, Obesity, Manchester Metropolitan University, Safety, A1C, SAN, Magnetic resonance imaging, Epidemiology, Nutcracker, Therapy, Phenotype, Cardiology, Cirrhosis, FACC, Risk, Vertex Pharmaceuticals, Hospital, CMA, DSM-IV codes, Patient, Diabetes, Sangamo Therapeutics, Science, Pharmacokinetics, Heart failure, Syndrome, Health, Eli Lilly, Messenger, University, Public health, Massachusetts General Hospital, Body composition, Body mass index, MASH, Type 2, Human, Type 2 diabetes, Management, Pharmaceutical industry, Lilly, Chorus

CHARLOTTESVILLE, Va. and SAN FRANCISCO, Nov. 15, 2023 /PRNewswire/ -- Rivus Pharmaceuticals Inc., a clinical-stage biopharmaceutical company dedicated to improving metabolic health, today announced key clinical and corporate updates. The company randomized the first patient in the Phase 2b M-ACCEL trial of HU6, an investigational controlled metabolic accelerator (CMA), in obese subjects with Type 2 diabetes and at risk of metabolic dysfunction-associated steatohepatitis (MASH). Additionally, Rivus appointed Robert J. Schott, M.D., M.P.H., FACC, chief medical officer and appointed Ian F. Smith chairman of the board of directors.

Key Points: 
  • Additionally, Rivus appointed Robert J. Schott, M.D., M.P.H., FACC, chief medical officer and appointed Ian F. Smith chairman of the board of directors.
  • Approximately 280 adult patients will be randomized 2:1:2:2 into one of four treatment groups (placebo, HU6 150 mg, HU6 300 mg or HU6 450 mg) and treated for six months (26 weeks).
  • "I am delighted to be joining Rivus Pharmaceuticals, where the devoted founders and their team have made rapid progress in advancing HU6 into the clinic," said Dr. Schott.
  • "I look forward to partnering with the Rivus leadership team and other board members as we pursue the company's mission to improve human metabolic health caused by obesity.

Dotmatics Launches GraphPad Prism 10 with a More Open File Format, Plus New Collaboration and Integration Capabilities

Retrieved on: 
Wednesday, November 15, 2023
Cloud, Research, Organization, GraphPad Software, Meta-analysis, Data analysis, CSV, Master of Science, Teaching, FAIR, Interdisciplinarity, MD, Epidemiology, PNG, ANOVA, Doctor of Philosophy, JSON, AI, Dotmatics, Publication, Collaboration, Telescopic sight, Medical device, Prism

BOSTON, Nov. 15, 2023 /PRNewswire/ -- Dotmatics, a leader in R&D scientific software connecting science, data, and decision-making, today announced a major new release of its popular GraphPad Prism application, the world's leading analysis and graphing solution for scientific research. Prism 10 introduces a number of features including a new, more open file format (.prism), a variety of core graphing and analysis improvements, and a beta for Prism Cloud. The enhanced functionality makes it easier for scientists using Prism to collaborate and integrate diverse data into their scientific workflows and applications. Learn more about the new capabilities at: https://www.graphpad.com/updates/prism-1000-release-notes.

Key Points: 
  • Prism 10 introduces a number of features including a new, more open file format (.prism), a variety of core graphing and analysis improvements, and a beta for Prism Cloud.
  • Prism is an advanced statistical analysis software designed to help scientists create graphs to visualize and analyze data.
  • In February, Dotmatics announced that its R&D platform was the very first to integrate directly with Prism.
  • The new, more open Prism file format helps organizations connect scientific workflows that allow for greater collaboration and interdisciplinary research.

Mercy Launches AI-Driven Texting Program to Prevent Chemo-Related Hospitalizations

Retrieved on: 
Wednesday, November 15, 2023
Holiday, Medicine, Research, Epidemiology, Biostatistics, Fatigue, Cardiovascular disease, Patient, Multimedia, Algorithm, Doctor of Philosophy, Mercy, Heart, Greenwood, Food and Drug Administration, Saint Louis University, Machine learning, Conference, Organ, Diarrhea, Cancer, Diagnosis, National Research Corporation, Pain, Transplant, Medicare, Family, Hospital, Physician, Microsoft, Knowledge, Fever, Diabetes, Public, Accountable care organization, Pharmacy, Medical device, Nursing, Food, Health

ST. LOUIS, Nov. 15, 2023 /PRNewswire/ --Chemotherapy is a lifesaving treatment for many cancer patients, but the side effects can lead to hospitalizations. Named The Chen Chemotherapy Model after lead data scientist Jiajing Chen, the new AI-driven texting platform is proving valuable at keeping patients out of the hospital by raising red flags before symptoms become severe. Click to see pictures of Chen and her family.

Key Points: 
  • Chen served Mercy for nearly four years before she lost her own battle to cancer earlier this year.
  • Once opted into the smart texting platform, patients receive a daily text for seven days, except weekends and holidays.
  • The new smart texting program using The Chen Chemotherapy Model is the first of many use cases made possible by the Mercy and Microsoft collaboration .
  • Prior to joining Mercy, Chen was a faculty member at the Saint Louis University Department of Health and Clinical Outcomes Research.

Syra Health Announces Third Quarter 2023 Financial Results

Retrieved on: 
Tuesday, November 14, 2023
EBITDA, Health education, E&I, Population health, Epidemiology, Conference call, Rural Business-Cooperative Service, Emergency, Mental health, Depreciation, EMR, Workforce, ASC, Benchmarking, GAAP, Radiology, IPO, Public health, Table, Growth, Health, Addiction, Digital health, Interest, Family, Table A, Mental, DBH, Pharmaceutical industry, Video game, Clothing, Nursing, SS Syren, Conference

CARMEL, Ind., Nov. 14, 2023 /PRNewswire/ -- Syra Health Corp. (NASDAQ: SYRA), ("Syra Health" or the "Company") a healthcare company addressing some of healthcare's most significant challenges by providing innovative services and technology solutions, today announced its financial results for the third quarter of 2023 for the period ended September 30, 2023.

Key Points: 
  • Conference call will be held today, Tuesday, November 14 at 9:00am ET
    CARMEL, Ind., Nov. 14, 2023 /PRNewswire/ -- Syra Health Corp. (NASDAQ: SYRA), ("Syra Health" or the "Company") a healthcare company addressing some of healthcare's most significant challenges by providing innovative services and technology solutions, today announced its financial results for the third quarter of 2023 for the period ended September 30, 2023.
  • Launched Syrenity, a mental health product that proactively identifies the negative factors impacting mental health and integrates telehealth for mental health prevention and treatment.
  • Sandeep Allam, Executive Chairman and President of Syra Health, said, "We completed our successful initial public offering in October 2023.
  • Net Loss for the quarter ended September 30, 2023, was $(354,376), compared to $(354,535) in the third quarter of 2022.

Lupus Foundation of America Awards Scientists for Notable Contributions to Lupus Research

Retrieved on: 
Sunday, November 12, 2023
Associate, Research, Jean, Lupus Foundation of America, Epidemiology, Disease, Cumming School of Medicine, Patient, Faculty, University of Calgary, Lupus, Division, Translational research, Science, Autoimmune disease, FRCPC, Weldon Humble, University, SLE, Lupus nephritis, MPH, Diagnosis, CDC, San Francisco Bay Area, LFA, Biomarker, University of California, Biology, Forestry, Nursing, Pharmaceutical industry, Rheumatology, MD

WASHINGTON, Nov. 12, 2023 /PRNewswire/ -- The Lupus Foundation of America (LFA) is pleased to recognize two leading lupus researchers at the 2023 Evelyn V. Hess Reception.

Key Points: 
  • WASHINGTON, Nov. 12, 2023 /PRNewswire/ -- The Lupus Foundation of America (LFA) is pleased to recognize two leading lupus researchers at the 2023 Evelyn V. Hess Reception.
  • She is the current chair of LuCIN, a network of academic institutions collaborating in the conduct of lupus clinical trials.
  • "As a practicing rheumatologist, I am passionate about lupus research because I see firsthand how this disease disproportionately impacts historically vulnerable communities.
  • Dr. Choi was funded by several career development awards including the Lupus Foundation of America Gary S. Gilkeson Career Development Award, during which she was supervised by her mentor, Dr. Karen Costenbader.

Kyverna Therapeutics Congratulates Scientific Advisory Board Member Peter A. Merkel, M.D., M.P.H. on Receiving the 2023 ACR Distinguished Clinical Investigator Award

Retrieved on: 
Saturday, November 11, 2023
Medicine, Research, Epidemiology, Therapy, University, Scleroderma, Patient, CD19, American College of Rheumatology, American College, Rheumatology, Lupus nephritis, ACR, Vasculitis, Pharmaceutical industry

EMERYVILLE, Calif., Nov. 11, 2023 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a patient-centered clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, congratulates Peter A. Merkel, M.D., M.P.H., a member of the Kyverna's scientific advisory board, on receiving the 2023 ACR Distinguished Clinical Investigator Award by the American College of Rheumatology (ACR). The recognition is given annually to a member who exhibits outstanding contributions to the field of rheumatology.

Key Points: 
  • The recognition is given annually to a member who exhibits outstanding contributions to the field of rheumatology.
  • "All of us at Kyverna celebrate this well-deserved recognition of Dr. Merkel's impact in the field of rheumatology," said Peter Maag, Ph.D., chief executive officer of Kyverna.
  • Dr. Merkel's research focuses on clinical trial design and conduct, outcome-measure development, clinical epidemiology, genetic epidemiology, and biomarker discovery.
  • Dr. Merkel has been a Kyverna Advisory Board member since 2022.

Global Healthy Living Foundation to Present Pioneering Patient-Centered Research at ACR Convergence 2023

Retrieved on: 
Thursday, November 9, 2023
Biometrics, Telemedicine, Virtual Medicine, Pharmaceutical, General Health, Health, Wearables, Mobile Technology, Technology, Other Health, Online, Rheumatism, American College, Hospital, Treatment, Face, Doctor of Philosophy, Medicine, Disease, Efficacy, COVID-19, Overalls, Culture, PRO, Pain, Medical Affairs Bureau, Gold, MPH, Impact, Additive effect, RA, American College of Rheumatology, Data management, Exercise, Patient, ACR, Plant, Rehabilitation, MD, Motivation, Mindfulness, Quality of life, Longitudinal study, Research, Osteoporosis, DSM-IV codes, Guideline, Rheumatoid arthritis, Role, TNF inhibitor, Pros, Conjoint analysis, Jaki, Poster, Ageing, WEAR, Pharmaceutical industry, Medical device, Medical imaging, Nursing, Dietary supplement, Diet, Rheumatology, Fatigue, Flare, Epidemiology, Arthritis

The Global Healthy Living Foundation and its digital, arthritis patient centered research registry, formerly ArthritisPower, will collaboratively present eight scientific abstracts and five patient perspective posters at the American College of Rheumatology Convergence 2023 (Philadelphia, PA, November 10-15, 2023).

Key Points: 
  • The Global Healthy Living Foundation and its digital, arthritis patient centered research registry, formerly ArthritisPower, will collaboratively present eight scientific abstracts and five patient perspective posters at the American College of Rheumatology Convergence 2023 (Philadelphia, PA, November 10-15, 2023).
  • Collectively, GHLF researchers will focus on innovative approaches to remote therapeutic monitoring, patient engagement, and personalized care in rheumatic and musculoskeletal diseases.
  • This study offers key insights on innovative disease tracking methods, including those that can happen outside traditional clinical settings, particularly for diseases like rheumatoid arthritis (RA).
  • GHLF anticipates engaging with fellow organizations and professionals at ACR Convergence to share their year-long accomplishments in rheumatic disease research.

LEADING HEALTHCARE AND EDUCATION EXPERT HARRIS PASTIDES JOINS HUB INTERNATIONAL AS STRATEGIC INDUSTRY ADVISOR

Retrieved on: 
Thursday, November 9, 2023
Council, Education, Health care, Council for International Exchange of Scholars, Public health, American Medical Association, Fulbright Program, Conference, Doctor of Philosophy, University, Popular Executive Committee of Valencia, Arnold School, Yale University, Trustee, Institute of International Education, Alumni, Medicine, Executive Committee, HUB, Degree, Episcopal conference, Harris Pastides, NCAA, Management, Nursing, Epidemiology

CHICAGO, Nov. 9, 2023 /PRNewswire/ -- Hub International Limited (HUB), a leading global insurance brokerage, announced today that Harris Pastides has joined as Strategic Industry Advisor.

Key Points: 
  • CHICAGO, Nov. 9, 2023 /PRNewswire/ -- Hub International Limited (HUB), a leading global insurance brokerage, announced today that Harris Pastides has joined as Strategic Industry Advisor.
  • "Harris has a strong reputation as a leading industry expert in healthcare and education," said Chris Treanor, HUB President of Programs & Specialties.
  • Pastides serves on several boards, chairs the Fulbright Program's Council for the International Exchange of Scholars and is on the Executive Committee of the Institute for International Education.
  • Pastides earned a Master of Public Health and PhD in Epidemiology from Yale University.

Increasing Incidence of Kidney Stone Disease Drives Growth in Stone Management Disposables Market, with Calcium Oxalate Stones Dominating - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 8, 2023
General Health, Pharmaceutical, Health, Surgery, Kidney stone disease, Cysteine, Ureteroscopy, Uric acid, Struvite, Epidemiology, Incidence, Region, URS, Internet, Urology, Country, Calcium oxalate, ASP, Abdomen, Kidney, Groin, Disease, Urine, COVID-19, SWOT, Segment, Market access, Forecast, PCNL, Blood, Nephrology, SWL, Woman, Pain, Patient, SWOT analysis, System, Retail, Health care

The model discusses in detail the impact of COVID-19 on Stone Management Disposables market for the year 2020 and beyond.

Key Points: 
  • The model discusses in detail the impact of COVID-19 on Stone Management Disposables market for the year 2020 and beyond.
  • Nephrolithiasis, or kidney stone disease, is a condition in which individuals form stones in the kidney or urinary tract.
  • Kidney stones can be classified based on their chemical composition: calcium oxalate, calcium phosphate, uric acid, cysteine, struvite.
  • Calcium oxalate stones are the most commonly formed stones and account for approximately 82% of stone cases.

Laboratory Testing and PCR Technology Lead the India Infectious Disease Diagnostics Market, Transforming Disease Detection and Management - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 8, 2023
Health, Infectious Diseases, Pathogen, Laboratory, Research, Public health surveillance, RPA, Molecular biology, Infection, Parasitism, Biomarker, Contact tracing, Research and development, CRISPR, PCR, Disease, Sputum, Fungus, Virulence, LAMP, Whole genome sequencing, Artificial intelligence, Vaccination, Urine, NGS, Diagnosis, COVID-19, Medicine, WGS, Blood, Microscopy, Public, Gene expression, DNA, Vaccine, Pharmaceutical industry, Epidemiology

The India emerging infectious disease diagnostics market is set for substantial growth over the forecast period from 2023 to 2033.

Key Points: 
  • The India emerging infectious disease diagnostics market is set for substantial growth over the forecast period from 2023 to 2033.
  • The India emerging infectious disease diagnostics market is currently in an emerging phase.
  • The India emerging infectious disease diagnostics market plays a pivotal role in modern biotechnology, clinical diagnostics, and pathogen research.
  • The India emerging infectious disease diagnostics market is segmented into key categories:
    In FY2022, laboratory testing was the dominant application segment in the India emerging infectious disease diagnostics market.